Welcome to our dedicated page for Reliance Global Group news (Ticker: EZRA), a resource for investors and traders seeking the latest updates and insights on Reliance Global Group stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Reliance Global Group's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Reliance Global Group's position in the market.
Reliance Global Group (NASDAQ: EZRA) completed a strategic investment through its LifeSci Global biotech division in Innervate Radiopharmaceuticals on May 4, 2026.
LifeSci Global agreed to acquire 421,053 shares at $4.75 (~$2.0 million total), with $500,000 funded at closing and staged follow-on funding rights. Innervate’s lead asset is 18F-mFBG for PET imaging in neuroblastoma; initial market opportunity ~$250M, with potential >$1B expansion markets and possible Priority Review Voucher upside. Interested directors recused; certain directors hold equity in LifeSci Global.
Reliance Global Group (Nasdaq: EZRA) increased its equity stake in Enquantum to approximately 29% after Enquantum met defined technical and commercial milestones on April 28, 2026. Reliance expects a pathway to a 51% fully diluted controlling interest if remaining milestones are met.
Enquantum set latency targets for its alpha: 20–80 microseconds for Kyber768 key generation/verification and ~1 microsecond for AEAD processing; AEAD lab testing and full benchmarking are forthcoming.
Reliance Global Group (NASDAQ: EZRA) will participate in the Centri Capital Conference at the Nasdaq MarketSite in New York City on April 14, 2026. Executives including Chairman and CEO Ezra Beyman will take part in a fireside chat at 2:30 PM ET and meet with investors throughout the day.
The one-day, invite-only event hosts emerging growth companies, institutional investors, family offices, and capital markets professionals for presentations, fireside chats, and one-on-one meetings focused on investment opportunities and long-term growth strategies.
Reliance Global Group (Nasdaq: EZRA) launched RELI Exchange 2.0 on March 25, 2026, upgrading its InsurTech platform to expand recruiting capacity, improve execution, and accelerate growth.
Key metrics: health policies written via RELI Exchange rose 72% YoY in 2025, Personal Lines P&C written premium increased 36% YoY, and the broker network grew from ~65 to ~300 agency partners since 2022.
The upgrade centralizes recruiting workflows, adds pipeline stages, integrated task management, and communication tracking to support higher volumes, faster follow-up, and future automation.
Reliance Global Group (Nasdaq: EZRA) funded the next milestone in its strategic investment in Enquantum, increasing its ownership by 4% to ~12% fully diluted and securing an additional board seat. The tranche-based agreement can increase Reliance to a 51% fully diluted controlling interest when all milestones complete or if Reliance accelerates funding.
Enquantum is advancing NIST-aligned, hardware-accelerated post-quantum cryptography for high-throughput environments and is engaging prospective partners in North America and planned implementations in southern Israel under the Scale51 commercialization plan.
Reliance Global Group (NASDAQ: EZRA) reported 2025 results and launched EZRA International Group to execute its Scale51 technology expansion strategy. The company closed an investment in Enquantum Ltd. with a pathway to majority control, signed a non-binding term sheet for Scentech Medical, completed divestitures to cut debt, and improved key balance sheet metrics.
2025 highlights: unrestricted cash ~$1.3M (+250%), working capital ~$1.9M (+351%), stockholders’ equity ~$6.4M (+114%), commission income $12.4M, net loss improved to $7.0M.
Reliance Global Group (NASDAQ: EZRA) will host a conference call on March 10, 2026 at 4:30 PM Eastern to discuss fourth quarter 2025 financial results and provide a business update. The call is available by telephone and webcast; replays will be accessible online and by telephone for specified windows.
Telephone access codes and webcast links are provided for live participation and replay through March 10, 2027 (webcast) and March 24, 2026 (telephone replay).
Reliance Global Group (Nasdaq: EZRA) closed its strategic acquisition of Enquantum Ltd. on Feb 23, 2026, starting a milestone-driven path toward a 51% fully diluted controlling interest.
Enquantum develops hardware-accelerated, NIST-aligned post-quantum encryption for terabit-scale environments and holds a 2025 patent for FPGA-based quantum-resistant communications.
Reliance Global Group (Nasdaq: EZRA) signed a definitive agreement to acquire a 51% controlling interest in post-quantum cybersecurity company Enquantum, with an aggregate purchase price of $2,125,000 payable over ~10 months via milestone-tied tranches.
The deal implies a $2,041,667 pre-money valuation and $9.8018 per-share purchase price; initial close yields an 8% fully diluted stake (including conversion of a $166,000 bridge note). Closing expected within 30 days and remains subject to customary conditions.
Reliance Global Group (Nasdaq: EZRA) launched Scale51, an operating and acquisition model within new subsidiary EZRA International Group to acquire controlling 51% stakes in technology companies and scale them in the U.S.
Target sectors include AI/data analytics, cybersecurity, FinTech/InsurTech, and MedTech; potential early transactions with Enquantum and Scentech remain subject to diligence and definitive agreements.